Encontró una tablet que no solo almacenaba memoria, sino que también la creaba. ¿Hasta dónde estarías dispuesto a llegar por un recuerdo perfecto? El Oráculo de los 24 Atardeceres El paquete llegó sin remitente, solo una etiqueta con su nombre: “ Dr. Alvaro Rojas , para sus atardeceres” . Adentro, envuelta en un silicio suave como terciopelo negro, estaba la Tablet Android 15 de 10.1 pulgadas . No parecía salida de una fábrica, sino cultivada . Su pantalla HD de 2560x1440 píxeles era un estanque de obsidiana líquida, profundo y listo para reflejar mundos. Alvaro, neurólogo retirado y viudo, la encendió. El Octa Core no roncó; susurró al ser activado. Pero el verdadero gancho no fue su velocidad, sino la primera notificación: *“ Memoria principal: 24GB . Memoria expandible detectada: +8GB . Espacio emocional disponible : Ilimitado. ¿Importar recuerdo clave?”*. Con un pulso tembloroso, Alvaro seleccionó el video más preciado de su archivo: ...
The Food and Drug Administration (FDA) has approved Leqembi (lecanemab-irmb), the first drug to slow the progression of Alzheimer's disease. Leqembi is a monoclonal antibody that targets amyloid-beta (Aβ), a protein that builds up in the brains of people with Alzheimer's disease. By binding to and eliminating Aβ, Leqembi helps to clear the plaques that are a hallmark of the disease.
Leqembi was approved under the FDA's accelerated approval pathway, which allows for the approval of drugs that show a clear benefit on a surrogate endpoint, such as Aβ reduction, even if the long-term benefits on clinical outcomes, such as memory and function, have not yet been established. The FDA's decision to approve Leqembi was based on data from two clinical trials, which showed that the drug was able to reduce Aβ plaques in the brains of people with Alzheimer's disease.
In the first trial, Leqembi was given to people with mild cognitive impairment (MCI) who were at high risk of developing Alzheimer's disease. After 18 months of treatment, people who received Leqembi had a slower decline in cognitive function than those who received a placebo. In the second trial, Leqembi was given to people with mild dementia. After 18 months of treatment, people who received Leqembi had a slower decline in cognitive function and daily function than those who received a placebo.
The most common side effects of Leqembi were infusion-related reactions, headache, and ARIA (amyloid-related imaging abnormalities). ARIA is a condition that can occur in people taking Leqembi, and it can cause temporary changes in brain imaging or symptoms such as headache, confusion, and dizziness.
Leqembi is administered by intravenous infusion every two weeks. The cost of Leqembi is not yet known, but it is likely to be expensive.
The approval of Leqembi is a significant advance in the treatment of Alzheimer's disease. While Leqembi does not cure the disease, it can slow its progression and help to preserve cognitive function. This is an important step forward for the millions of people who are affected by Alzheimer's disease.
What does this mean for patients?
The approval of Leqembi is a major breakthrough for patients with Alzheimer's disease. For the first time, there is a drug that has been shown to slow the progression of the disease. This means that patients who are diagnosed with Alzheimer's disease may now have a chance to preserve their cognitive function for a longer period of time.
Of course, Leqembi is not a cure for Alzheimer's disease. It is still a progressive disease, and patients will eventually experience decline. However, Leqembi can help to slow that decline and give patients more time to live their lives to the fullest.
What does this mean for the future of Alzheimer's treatment?
The approval of Leqembi is a sign of hope for the future of Alzheimer's treatment. It shows that it is possible to develop drugs that can target the underlying causes of the disease. This is a major step forward, and it is likely that other drugs that target amyloid-beta or other pathways involved in Alzheimer's disease will be developed in the future.
The approval of Leqembi is also a reminder that there is still much work to be done in the fight against Alzheimer's disease. The disease is still a major cause of disability and death, and there is no cure. However, the approval of Leqembi is a sign that progress is being made, and it gives hope to patients and their families.
What is the Leqembi treatment?
Leqembi (lecanemab-irmb) is a monoclonal antibody that targets amyloid-beta (Aβ), a protein that builds up in the brains of people with Alzheimer's disease. By binding to and eliminating Aβ, Leqembi helps to clear the plaques that are a hallmark of the disease.
Leqembi was approved by the FDA in 2022 for the treatment of Alzheimer's disease in people with mild cognitive impairment (MCI) or mild dementia who have amyloid plaques in their brains. The drug is administered by intravenous infusion every two weeks.
The most common side effects of Leqembi are infusion-related reactions, headache, and ARIA (amyloid-related imaging abnormalities). ARIA is a condition that can occur in people taking Leqembi, and it can cause temporary changes in brain imaging or symptoms such as headache, confusion, and dizziness.
Leqembi is not a cure for Alzheimer's disease, but it can slow the progression of the disease and help to preserve cognitive function. The drug is currently available through the Medicare Part B prescription drug benefit.
Here are some key facts about Leqembi:
- It is the first drug to slow the progression of Alzheimer's disease.
- It is administered by intravenous infusion every two weeks.
- The most common side effects are infusion-related reactions, headache, and ARIA.
- Leqembi is not a cure for Alzheimer's disease, but it can slow the progression of the disease and help to preserve cognitive function.
If you are considering Leqembi for the treatment of Alzheimer's disease, talk to your doctor about the risks and benefits of the drug.
How does the drug Leqembi work?
Leqembi (lecanemab-irmb) is a monoclonal antibody that targets amyloid-beta (Aβ), a protein that builds up in the brains of people with Alzheimer's disease. By binding to and eliminating Aβ, Leqembi helps to clear the plaques that are a hallmark of the disease.
Aβ is a small protein that is normally broken down and removed from the brain. However, in people with Alzheimer's disease, Aβ builds up and forms plaques. These plaques can damage neurons and lead to cognitive decline.
Leqembi works by binding to Aβ and preventing it from forming plaques. The drug is also thought to help clear existing plaques from the brain.
Leqembi was approved by the FDA in 2022 for the treatment of Alzheimer's disease in people with mild cognitive impairment (MCI) or mild dementia who have amyloid plaques in their brains. The drug is administered by intravenous infusion every two weeks.
The most common side effects of Leqembi are infusion-related reactions, headache, and ARIA (amyloid-related imaging abnormalities). ARIA is a condition that can occur in people taking Leqembi, and it can cause temporary changes in brain imaging or symptoms such as headache, confusion, and dizziness.
Leqembi is not a cure for Alzheimer's disease, but it can slow the progression of the disease and help to preserve cognitive function. The drug is currently available through the Medicare Part B prescription drug benefit.
Here is a summary of how Leqembi works:
- Leqembi binds to Aβ, a protein that builds up in the brains of people with Alzheimer's disease.
- This binding prevents Aβ from forming plaques.
- Leqembi also helps to clear existing plaques from the brain.
- This can help to slow the progression of Alzheimer's disease and preserve cognitive function.
If you are considering Leqembi for the treatment of Alzheimer's disease, talk to your doctor about the risks and benefits of the drug.
Source: bard.google.com
Comments
Post a Comment